Hurel Lands Second Big Pharma Partner in Quest To Bring Human Biochip to Drug-Discovery Market | GenomeWeb
Fledgling biotech firm Hurel this week said that the Schering Plough Research Institute, will join what it calls a “joint scientific collaboration” to help it further develop and test its microfluidics-based “human-on-a-chip” cell-based assay technology for drug discovery.
 
Schering is the second big pharma to become a partner since Hurel introduced the technology in early 2005 and began seeking early-access partners to help bring it to market. The first, penned in early 2005, was Johnson & Johnson.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.